Amol Akhade shared a post on LinkedIn:
”Oligometastatic NSCLC.
How to define it (Oligorecurrent, oligopersistant, oligoresidual and oligoprogressive) and some clinical evidence to approach it.
Oligometastatic NSCLC needs MDT and some of these patients do very well.”
Source: Amol Akhade/LinkedIn
Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
